Dr Trinidad Montero-Melendez

Profile

LinkedIn
Loop Research Network
ORCID iD: 0000-0002-3563-376X

Trinidad trained as a Pharmacologist and obtained her PhD in Biochemistry and Molecular Biology at the University of Granada, Spain. She later joined the William Harvey Research Institute to work on understanding the pro-resolving potential of melanocortin receptors. During that period, she discovered the pro-resolving activities of the molecule AP1189 and its novel biased mode of action, which entered clinical development shortly after.

In collaboration with several biotech and pharmaceutical companies, she has also contributed to the pre-clinical development of several other drug candidates for the treatment of inflammatory conditions and has participated in large high-throughput drug screening programmes for the identification of novel pro-resolving drugs. Another contribution to science includes the discovery of a novel mechanism of induction of senescence in synovial fibroblasts with therapeutic potential in diseases like rheumatoid arthritis. Her research is now focused on autoimmune diseases associated with chronic inflammation, and in developing innovative drugs that can target common mechanisms on autoimmune diseases.

Trinidad has published over 40 peer-reviewed publications as well as articles for the general public and children in the magazines The Biochemist and Frontiers for Young Minds. She also founded AutoImmunity Research Advisors (AIRA), a patient and public involvement and engagement group, focused on autoimmune diseases.

Trinidad is the teaching Lead on the module The Business of Pharmacology, on the Pharmacology and Innovative Therapeutics Program, has served as guest Associate Editor of several journals and sat at funding panels, among other contributions.

Other Roles:

• Director William Harvey Research Limited
• Governing Board Centre for Inflammation and Therapeutic Innovation (CiTI)
  
  
• Member of the William Harvey Research Foundation
• Member of the Versus Arthritis College of Experts
• Member of ICSA -International Cellular Senescence Association
  
  

Research

Group members

• Dr Camilla SA Davan-Wetton, Postdoctoral Scientist; ORCID: 0000-0003-1252-7136; X: @mdavanwetton
• Dr Natalya Khodeneva, Postdoctoral Scientist; ORCID: 0000-0002-1217-2286
• Dr Nicholas J Day, Postdoctoral Scientist; ORCID: 0000-0002-1553-8685; X: @nickday97
• Dr Mohammed T Hussain, Postdoctoral Scientist; ORCID: 0000-0002-8444-1414 

Drug Discovery and Development – Resolution Pharmacology

Melanocortin (MC) agonists are part of the Resolution Pharmacology concept which postulates that therapeutic strategies focused on the active promotion of our body’s endogenous pro-resolving mechanisms may lead to better and safer drugs. Melanocortin ligands act on five different MC receptors (MC_1-5), which belong to the G-protein couple receptors (GPCR) family. Their GPCR nature, wide-spread tissue distribution and participation in multiple biological processes, make these receptors highly druggable. Indeed, a few MC compounds are now approved for clinical use for conditions like erythropoietic protoporphyria (EPP) or for severe obesity.

In our lab, we work on the development of new compounds targeting the MC system, either by running our own drug development pipelines, or in close collaboration with industrial partners, by contributing to target characterization, identification of mode of actions or conducting pre-clinical evaluation of novel candidates.

Common Mechanisms to Autoimmune Diseases

Autoimmune diseases (AD), like rheumatoid arthritis or lupus, do not come alone. Chances are that 1 out of 4 patients suffering from an AD will develop additional ones throughout their lives. Better understanding of the shared causes across different ADs will not only increase our knowledge on why these diseases occur together but could also guide the development of new therapies that could be effective across several ADs.

The melanocortin peptide adrenocorticotropin hormone (ACTH) can be used to treat several ADs including rheumatoid arthritis and multiple sclerosis, although its use is very limited because ACTH also activates the stress hormone ‘cortisol’, causing serious side effects. In our lab we work to create novel melanocortin agonists devoid of those side effects so that these drugs could be safely used for long-term chronic inflammatory conditions which are typically associated with ADs, like for example rheumatoid arthritis, fibrosis or inflammatory bowel disease.

Melanocortins, senescence and tissue repair

Over the last 15 years, we have advanced the field on melanocortin research by discovering the pro-resolving actions of melanocortin agonists and by contributing to the identification of novel modes of action of MC drugs, including allosteric modulation or biased agonism.

More recently, we discovered a new action of a selective MC₁ agonist which is the induction of a cellular senescence-like phenotype in aberrantly activated fibroblasts, favouring the resolution of inflammation in models of arthritis and the acquisition of a pro-repair phenotype.

We are currently investigating the detailed mode of action of this novel mechanism and exploring other conditions for therapeutic application to scale up the translational impact of this discovery.

Pharmacogenomics and Precision Medicine

The melanocortin receptor MC₁ is encoded by a highly polymorphic gene for which more than 900 genetic variants (SNPs) have been identified. MC₁ is highly expressed in melanocytes, the skin cells responsible for the production of melanin. Many of these variants cause a loss-of-function on the receptor leading to reduced production of melanin. MC₁ gene variation is responsible for the diversity in human normal pigmentation, reflected in skin and hair colour, and it is strongly associated with red hair. MC₁ is mainly responsible for the tanning response upon UV stimulation, and it is strongly associated with skin cancer risk. However, the high frequency of these variants in the population may impact on the development of MC₁- based therapies.

We are investigating what is the impact of carrying a variant on MC1R gene on the anti-inflammatory properties of melanocortin drugs to find out if precision medicine approaches based on MC1R genotype would provide better therapeutic options by ensuring giving the right drug to the right patient.

Publications

• Thomas BL, Montero‐Melendez T, Oggero S et al. (2024). Molecular Determinants of Neutrophil Extracellular Vesicles That Drive Cartilage Regeneration in Inflammatory Arthritis. nameOfConference

  
  

  DOI: 10.1002/art.42958

  
  

  QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/98715
• Davan-Wetton CSA, Montero-Melendez T (publicationYear). An optimised protocol for the detection of lipofuscin, a versatile and quantifiable marker of cellular senescence. nameOfConference

  
  

  DOI: 10.1371/journal.pone.0306275

  
  

  QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/98328
• Rinne P, Taylor AW, Montero-Melendez T (publicationYear). Editorial: Melanocortins and melanocortin receptors in the regulation of inflammation: mechanisms and novel therapeutic strategies. nameOfConference

  
  

  DOI: 10.3389/fimmu.2023.1226886

  
  

  QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/89069
• Khodeneva N, Sugimoto MA, Davan-Wetton CSA et al. (publicationYear). Melanocortin therapies to resolve fibroblast-mediated diseases. nameOfConference

  
  

  DOI: 10.3389/fimmu.2022.1084394

  
  

  QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/84841
• Garrido-Mesa J, Thomas BL, Dodd J et al. (publicationYear). Pro-resolving and anti-arthritic properties of the MC1 selective agonist PL8177. nameOfConference

  
  

  DOI: 10.3389/fimmu.2022.1078678

  
  

  QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/83451
• Montero-Melendez T, Boesen T, Jonassen TEN (2022). Translational advances of melanocortin drugs: Integrating biology, chemistry and genetics. nameOfConference

  
  

  DOI: 10.1016/j.smim.2022.101603

  
  

  QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/77643
• Marques RM, Gonzalez-Nunez M, Walker ME et al. (2021). Loss of 15-lipoxygenase disrupts Treg differentiation altering their pro-resolving functions. nameOfConference

  
  

  DOI: 10.1038/s41418-021-00807-x

  
  

  QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/73147
• Oggero S, de Gaetano M, Marcone S et al. (2021). Extracellular vesicles from monocyte/platelet aggregates modulate human atherosclerotic plaque reactivity. nameOfConference

  
  

  DOI: 10.1002/jev2.12084

  
  

  QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/72444
• Davan-Wetton CSA, Pessolano E, Perretti M et al. (2021). Senescence under appraisal: hopes and challenges revisited. nameOfConference

  
  

  DOI: 10.1007/s00018-020-03746-x

  
  

  QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/69892
• Montero Melendez T, Nagano A, Chelala C et al. (2020). Therapeutic senescence via GPCR activation in synovial fibroblasts facilitates resolution of arthritis. nameOfConference

  
  

  DOI: 10.1038/s41467-020-14421-x

  
  

  QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/62896
• MONTERO MELENDEZ T (2018). MAY INFLAMMATION BE WITH YOU!. nameOfConference

  
  

  DOI: 10.3389/frym.2018.00051

  
  

  QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/55608
• Patruno S, Garrido-Mesa J, Romano M et al. (2018). Ligand bias and its association with pro-resolving actions of melanocortin drugs. nameOfConference

  
  

  DOI: 10.3389/fphar.2018.00919

  
  

  QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/43647
• Perretti M, Montero-Melendez T (2017). Resolution in an 'over-inflamed' era. nameOfConference

  
  

  DOI: 10.1042/bio03904004

  
  

  QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/43048
• Kaneva MK, Greco KV, Headland SE et al. (2017). Identification of Novel Chondroprotective Mediators in Resolving Inflammatory Exudates. nameOfConference

  
  

  DOI: 10.4049/jimmunol.1601111

  
  

  QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/22622
• Montero-Melendez T, Forfar RAE, Cook JM et al. (2017). Old drugs with new skills: fenoprofen as an allosteric enhancer at melanocortin receptor 3. nameOfConference

  
  

  DOI: 10.1007/s00018-016-2419-3

  
  

  QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/19607
• Simeoli R, Raso GM, Pirozzi C et al. (2017). An orally administered butyrate‐releasing derivative reduces neutrophil recruitment and inflammation in dextran sulphate sodium‐induced murine colitis. nameOfConference

  
  

  DOI: 10.1111/bph.13637

  
  

  QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/43044
• Madeira MFM, Queiroz-Junior CM, Montero-Melendez T et al. (2016). Melanocortin agonism as a viable strategy to control alveolar bone loss induced by oral infection. nameOfConference

  
  

  DOI: 10.1096/fj.201600790R

  
  

  QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/16159
• MONTERO MELENDEZ T, Buckley CD, Filer A et al. (2016). TARGETING SYNOVIAL FIBROBLASTS WITH MELANOCORTIN DRUGS. Annual European Congress of Rheumatology EULAR 2016

  
  

  DOI: 10.1136/annrheumdis-2016-eular.3231

  
  

  QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/62897
• Perretti M, Leroy X, Bland EJ et al. (2015). Resolution Pharmacology: Opportunities for Therapeutic Innovation in Inflammation. nameOfConference

  
  

  DOI: 10.1016/j.tips.2015.07.007

  
  

  QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/43045
• Haas R, Smith J, Rocher-Ros V et al. (publicationYear). Lactate Regulates Metabolic and Pro-inflammatory Circuits in Control of T Cell Migration and Effector Functions. nameOfConference

  
  

  DOI: 10.1371/journal.pbio.1002202

  
  

  QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/8009
• Montero-Melendez T, Gobbetti T, Cooray SN et al. (2015). Biased agonism as a novel strategy to harness the proresolving properties of melanocortin receptors without eliciting melanogenic effects.. nameOfConference

  
  

  DOI: 10.4049/jimmunol.1402645

  
  

  QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/17994
• Montero-Melendez T (2015). ACTH: The forgotten therapy. nameOfConference

  
  

  DOI: 10.1016/j.smim.2015.02.003

  
  

  QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/43047
• Montero-Melendez T, Madeira MFM, Norling LV et al. (2014). Association between periodontal disease and inflammatory arthritis reveals modulatory functions by melanocortin receptor type 3.. nameOfConference

  
  

  DOI: 10.1016/j.ajpath.2014.04.009

  
  

  QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/43046
• Montero-Melendez T, Perretti M (2014). Gapdh gene expression is modulated by inflammatory arthritis and is not suitable for qPCR normalization.. nameOfConference

  
  

  DOI: 10.1007/s10753-014-9829-x

  
  

  QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/43007
• Montero-Melendez T, Perretti M (2014). Connections in pharmacology: innovation serving translational medicine.. nameOfConference

  
  

  DOI: 10.1016/j.drudis.2013.11.022

  
  

  QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/43063
• Haas R, Smith J, Rocher-Ros V et al. (2014). How the microenvironment contributes to the establishment of chronic inflammatory diseases: lactate regulates metabolic and pro-inflammatory circuits in control of T cell migration and functions. nameOfConference

  
  

  DOI: doi

  
  

  QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/6636
• Dalli J, Norling LV, Montero-Melendez T et al. (2014). Microparticle alpha-2-macroglobulin enhances pro-resolving responses and promotes survival in sepsis.. nameOfConference

  
  

  DOI: 10.1002/emmm.201303503

  
  

  QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/10756
• Cooray SN, Gobbetti T, Montero-Melendez T et al. (2013). Ligand-specific conformational change of the G-protein-coupled receptor ALX/FPR2 determines proresolving functional responses.. nameOfConference

  
  

  DOI: 10.1073/pnas.1308253110

  
  

  QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/11983
• Dalli J, Montero-Melendez T, Norling LV et al. (2013). Heterogeneity in neutrophil microparticles reveals distinct proteome and functional properties.. nameOfConference

  
  

  DOI: 10.1074/mcp.M113.028589

  
  

  QMRO: qmroHref
• Montero-Melendez T, Dalli J, Perretti M (2013). Gene expression signature-based approach identifies a pro-resolving mechanism of action for histone deacetylase inhibitors.. nameOfConference

  
  

  DOI: 10.1038/cdd.2012.154

  
  

  QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/19645
• Calleja MA, Vieites JM, Montero-Meléndez T et al. (2013). The antioxidant effect of β-caryophyllene protects rat liver from carbon tetrachloride-induced fibrosis by inhibiting hepatic stellate cell activation.. nameOfConference

  
  

  DOI: 10.1017/S0007114512001298

  
  

  QMRO: qmroHref
• Rhodes DH, Pini M, Castellanos KJ et al. (2013). Adipose tissue-specific modulation of galectin expression in lean and obese mice: evidence for regulatory function.. nameOfConference

  
  

  DOI: 10.1002/oby.20016

  
  

  QMRO: qmroHref
• Schutters K, Kusters DHM, Chatrou MLL et al. (2013). Cell surface-expressed phosphatidylserine as therapeutic target to enhance phagocytosis of apoptotic cells.. nameOfConference

  
  

  DOI: 10.1038/cdd.2012.107

  
  

  QMRO: qmroHref
• Ahmed TJ, Montero-Melendez T, Perretti M et al. (2013). Curbing Inflammation through Endogenous Pathways: Focus on Melanocortin Peptides.. nameOfConference

  
  

  DOI: 10.1155/2013/985815

  
  

  QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/32370
• Montero-Meléndez T, Llor X, García-Planella E et al. (2013). Identification of novel predictor classifiers for inflammatory bowel disease by gene expression profiling.. nameOfConference

  
  

  DOI: 10.1371/journal.pone.0076235

  
  

  QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/71886
• Perretti M, Dalli J, Norling LV et al. (2013). Neutrophil Microparticles are heterogenous in content and function. nameOfConference

  
  

  DOI: 10.1096/fasebj.27.1_supplement.138.5

  
  

  QMRO: qmroHref
• Al-Kashi A, Montero-Melendez T, Moradi-Bidhendi N et al. (2013). The calcitonin and glucocorticoids combination: mechanistic insights into their class-effect synergy in experimental arthritis.. nameOfConference

  
  

  DOI: 10.1371/journal.pone.0054299

  
  

  QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/5205
• de Lima CB, Tamura EK, Montero-Melendez T et al. (2012). Actions of translocator protein ligands on neutrophil adhesion and motility induced by G-protein coupled receptor signaling.. nameOfConference

  
  

  DOI: 10.1016/j.bbrc.2011.12.078

  
  

  QMRO: qmroHref
• Dalli J, Montero-Melendez T, McArthur S et al. (2012). Annexin A1 N-terminal derived Peptide ac2-26 exerts chemokinetic effects on human neutrophils.. nameOfConference

  
  

  DOI: 10.3389/fphar.2012.00028

  
  

  QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/18353
• Vessillier S, Adams G, Montero-Melendez T et al. (2012). Molecular engineering of short half-life small peptides (VIP, αMSH and γ₃MSH) fused to latency-associated peptide results in improved anti-inflammatory therapeutics.. nameOfConference

  
  

  DOI: 10.1136/annrheumdis-2011-200100

  
  

  QMRO: qmroHref
• Patel HB, Montero-Melendez T, Greco KV et al. (2011). Melanocortin receptors as novel effectors of macrophage responses in inflammation. nameOfConference

  
  

  DOI: 10.3389/fimmu.2011.00041

  
  

  QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/29119
• Montero-Melendez T, Patel HB, Seed M et al. (2011). The melanocortin agonist AP214 exerts anti-inflammatory and proresolving properties.. nameOfConference

  
  

  DOI: 10.1016/j.ajpath.2011.03.042

  
  

  QMRO: qmroHref
• Rhodes D, Pini M, Montero-Melendez T et al. (2011). EXPRESSION OF ANNEXIN A1 IN ADIPOSE TISSUE IS DISSOCIATED FROM MACROPHAGE INFILTRATION DURING DEVELOPMENT OF OBESITY IN MICE. nameOfConference

  
  

  DOI: doi

  
  

  QMRO: qmroHref
• Montero-Melendez T, Jonassen T, Seed M et al. (2011). MC3 AGONISTS AS NOVEL PRO-RESOLVING THERAPEUTICS. nameOfConference

  
  

  DOI: doi

  
  

  QMRO: qmroHref
• Greco KV, Montero-Melendez T, Patel H et al. (2011). MELANOCORTIN RECEPTOR AGONISTS ARE NOVEL CHONDROPROTECTIVE THERAPEUTICS. nameOfConference

  
  

  DOI: doi

  
  

  QMRO: qmroHref
• Vessillier S, Adams G, Montero-Melendez T et al. (2011). MOLECULAR ENGINEERING OF SHORT HALF LIFE SMALL PEPTIDES (VIP, alpha MSH AND gamma 3MSH) INTO LATENT ASSOCIATED PEPTIDE (LAP) RESULTS IN TARGETED ANTI-INFLAMMATORY AND ANTI-RHEUMATIC THERAPEUTICS. nameOfConference

  
  

  DOI: doi

  
  

  QMRO: qmroHref
• Montero-Melendez T, Patel HB, Perretti M (2011). Role of melanocortin receptors in the regulation of gouty inflammation.. nameOfConference

  
  

  DOI: 10.1007/s11926-011-0163-0

  
  

  QMRO: qmroHref
• Patel HB, Montero-Melendez T, Greco KV et al. (2011). Melanocortin receptors as novel effectors of macrophage responses in inflammation.. nameOfConference

  
  

  DOI: 10.3389/fimmu.2011.00041

  
  

  QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/25546
• Renshaw D, Montero-Melendez T, Dalli J et al. (2010). Downstream gene activation of the receptor ALX by the agonist annexin A1.. nameOfConference

  
  

  DOI: 10.1371/journal.pone.0012771

  
  

  QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/10712
• Suarez Garcia A, MONTERO MELENDEZ T (2010). Tratado de Nutrición. 2a ed. Tomo I: Bases Fisiológicas y Bioquímicas de la Nutrición.(Encuadernación: Rústica). nameOfConference

  
  

  DOI: doi

  
  

  QMRO: qmroHref
• Patel HB, Leoni G, MONTERO MELENDEZ T et al. (2010). Melanocortins. nameOfConference

  
  

  DOI: doi

  
  

  QMRO: qmroHref
• Patel HB, Leoni G, Montero-Melendez T et al. (2010). Melanocortin control of cell trafficking in vascular inflammation.. nameOfConference

  
  

  DOI: 10.1007/978-1-4419-6354-3_7

  
  

  QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/43049
• Gila A, Aguilera CM, Tofe I et al. (2008). Altered gene expresión associated with lipid metabolism in adipose tissue of obese children.. 18th Annual Meeting of the European Childhood Obesity Group

  
  

  DOI: doi

  
  

  QMRO: qmroHref
• Montero T, Llor X, Suarez A (2008). Gene-expression signature-based approach identifies pro-apoptotic compounds in Caco-2 cell line.. Digestive Diseases Week 2008

  
  

  DOI: doi

  
  

  QMRO: qmroHref
• Gil A, Aguilera CM, Montero T et al. (2007). Altered Gene Expression Associated with Inflammation in Adipose Tissue of Obese Children.. 17th Annual Meeting of the European Chilhood Obesity Group (ECOG)

  
  

  DOI: doi

  
  

  QMRO: qmroHref
• Montero T, Vieites JM, Llor X et al. (2007). Comparative genomic analysis of rat IBD models identifies new genes and biological processes as potential therapeutic targets.. Digestive Diseases Week 2007

  
  

  DOI: doi

  
  

  QMRO: qmroHref
• Montero T, Vieites JM, Sanchez de Medina F et al. (2007). Genomic expression analysis reveals new molecular and cellular events involved in the pathogenesis of DSS-induced colitis.. Digestive Diseases Week 2007

  
  

  DOI: doi

  
  

  QMRO: qmroHref
• Montero T, Vieites JM, Llor X et al. (2006). A comparative genomic perspective on murine inflammatory bowel disease models.. Digestive Diseases Week 2006

  
  

  DOI: doi

  
  

  QMRO: qmroHref
• Montero T, Vieites JM, Llor X et al. (2006). Análisis genómico comparativo de varios modelos animales de Enfermedad Inflamatoria Intestinal.. Digestive Diseases Week: LXV Congress of the Spanish Society of Digestive Pathology

  
  

  DOI: doi

  
  

  QMRO: qmroHref
• Montero T, Aguilera CM, Suarez A et al. (2006). Changes in the Expression of Genes Related to Insulin Signaling in Adipose Tissue of Obese Children.. 16th Annual Meeting of the European Chilhood Obesity Group (ECOG)

  
  

  DOI: doi

  
  

  QMRO: qmroHref
• Montero T, Martinez O, Vieites JM et al. (2006). Efectos de la sulfasalazina en el perfil de expresión génica de la colitis inducida por ácido trinitrobencenosulfónico en ratas.. Digestive Diseases Week: LXV Congress of the Spanish Society of Digestive Pathology

  
  

  DOI: doi

  
  

  QMRO: qmroHref
• Martinez O, Montero T, Suarez A et al. (2006). Effect of sulfasalazine on the colonic transcriptome in rat TNBS colitis.. Digestive Diseases Week 2007

  
  

  DOI: doi

  
  

  QMRO: qmroHref
• Vieites JM, de la Torre R, Ortega MA et al. (2003). Characterization of human cd200 glycoprotein receptor gene located on chromosome 3q12-13. nameOfConference

  
  

  DOI: doi

  
  

  QMRO: qmroHref

Collaborators

Internal

• Prof Mauro Perretti (QMUL)
• Prof Xavier Griffins (QMUL)

External

• Prof David Abraham (UCL)
• Prof Andrew Filer (University of Birmingham)
• Prof Thomas Jonassen (University of Copenhagen)
  
  

News

• Press release on Connect Immune Research Award.
• Press release on new collaboration with SynAct Pharma – Pharmacogenomics Program.
• Press release on publication of article in American Journal of Pathology.
• Press release on acquisition by Pfizer of our drug screening programme.

Teaching

Module Lead

• The Business of Pharmacology (BMD271) – BSc Pharmacology and Innovative Therapeutics 

Lecturer

• MSc Clinical Drug Development
• MSc Healthcare Research Methods

Other

• PBL Tutor
• Academic Advisor

Disclosures

• 2021 - current: Received research funds from SynAct Pharma AB
• 2020 - current: Performed expert consultancy activity for SynAct Pharma AB
• 2019: Performed expert consultancy activity for NeuroCreate Ltd (QConsult)
• 2018: Performed expert consultancy activity for Palatin Technologies Inc
• 2017- 2018: Performed expert consultancy activity for ResoTher Pharma
• 2016: Performed expert consultancy activity for Mallinckdrodt Pharmaceuticals